Angioshield First-In-Human Study to Demonstrate the Preliminary Safety and Efficacy


The purpose of this study is to determine whether or not the Angioshield device can be safely applied to support saphenous vein grafts used in standard coronary bypass surgery.

Full Title of Study: “First-In-Human Study to Demonstrate the Preliminary Safety and Efficacy of the Angioshield System to Provide Mechanical Support for Vein Grafts Used in CABG Surgery”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: September 2014

Detailed Description

This is a first in human study which is intended to determine if a larger pivotal study is justified.


  • Device: Angioshield
    • The Angioshield wrap provides external structural support for the saphenous vein graft used in CABG surgery and is intended to prevent over distention of the graft under arterial pressure, potentially improving graft patency and reducing the likelihood of graft failure.

Arms, Groups and Cohorts

  • Experimental: Device Applied
    • All participants will be treated with the Angioshield

Clinical Trial Outcome Measures

Primary Measures

  • MACE
    • Time Frame: 30 days
    • The primary objective of this study is to provide acute and subacute (up to 30 days) safety outcomes to support expansion to a pivotal study involving a larger subject population. All Major Adverse Cardiac Events (MACE), defined as the composite of cardiac death, myocardial infarction (Q-wave and non-Q wave), and target vessel revascularization, will be evaluated at 30 days post-operative.

Secondary Measures

  • MACE and Graft Patency
    • Time Frame: 30, 90 and 365 Days
    • The secondary objective of this study is to assess long term (up to 1 year) safety outcomes and vein patency for additional safety and preliminary efficacy information. All MACE, defined as the composite of cardiac death, myocardial infarction (Q-wave and non-Q wave), and target vessel revascularization will be evaluated at 90 and 365 days and to assess patency of the treated saphenous vein graft at 30, 90 and 365 days

Participating in This Clinical Trial

Inclusion Criteria

Subject will be eligible for inclusion in the investigation if he/she:

  • is between the ages of 18 and 80 years of age, inclusive – requires Coronary Atery Bypass Graft (CABG) surgery with minimum of one SVG used to bypass a stenosis in the Right Coronary, the Circumflex, a Diagonal, or an Obtuse Marginal artery, due to atherosclerotic coronary artery disease – is able to give their informed written consent – is willing and able to complete all follow-up visits and procedures Exclusion Criteria:

Subject will be excluded from participation in the investigation if he/she:

  • is currently enrolled in another clinical investigation – is unable to tolerate or comply with required post-surgical medications or imaging (e.g., anticoagulation regimen; or known allergy to contrast agent) – is or may be pregnant or is lactating, or plans to become pregnant in the next 12 months – shows a presence of hypercoagulable state or history of idiopathic venous or arterial thrombosis – has had an acute MI within the last 21 days – has had a previous CABG – requires emergency surgery – has a left ejection fraction (LEF) less than 20% – has a target vessel stenosis of less than 70% – has a transmural infarct of the target artery territory – currently requiring dialysis – is having concomitant-surgery of any kind – has varicose veins – has had previous saphenectomy

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 80 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Neograft Technologies, Incorporated
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Jerzy Sadowski, MD, PhD, Principal Investigator, Pope John Paul II Hospital and Cardiology Collegium Medicum Jagiellonian University, Krakow, Poland

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.